Enzalutamide reduced metastasis or death risk by 71 percent in phase III trial of castration-resistant nonmetastatic prostate cancer with escalating PSA. Source link
Using a range of tools, researchers identify a plausible mechanism and genes through which a genetic variation influences prostate cancer aggressiveness. Source link
A new clinical trial proves the benefits of an innovative form of radiotherapy that reduces the treatment to five sessions instead of the usual 37.